Liposomal amphotericin B for aspergillosis with liver problems
Part of Digestive system clinical trials.
This trial tests a medication called liposomal amphotericin B for people with a serious fungal infection (aspergillosis) who also have liver problems. The goal is to see if this treatment is safe and effective for them.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older and in the intensive care unit (ICU).
- You must have a confirmed or highly suspected aspergillus infection.
- Your liver function must be abnormal, with certain elevated liver enzymes or a Child-Pugh score of A or B.
- You must be expected to receive antifungal treatment for at least 5 days.
- You cannot be pregnant or breastfeeding, and cannot have a severe kidney problem or be on dialysis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a combination of inhaled liposomal amphotericin B (Ambisome) plus itraconazole works better for chronic pulmonary aspergillosis (CPA). It may help control long-term Aspergillus lung infection and symptoms.
This trial looks at how a specific antifungal medicine, called liposomal amphotericin B, given over a longer period, helps prevent serious fungal infections in people undergoing treatment for cancer or receiving a stem cell transplant. It may be an option if you are at high risk for these infections.
This trial tests the safety and effectiveness of a medicine called liposomal amphotericin B for treating serious mold infections in liver transplant recipients. It compares this medicine to another antifungal called voriconazole, and may help find the best way to treat these infections after a liver transplant.
This research study tracks how a inhaled antifungal medicine (amphotericin B in a special lipid form) deposits and distributes in the lungs of people with chronic pulmonary aspergillosis—a long-term fungal lung infection. The goal is to understand if this inhaled approach can effectively treat this condition.
This study looks at how well a medicine called liposomal amphotericin B works for treating serious fungal infections in people who have had a solid organ transplant. It may help doctors understand the best way to use this medicine for patients like you.
This study compares two inhaled treatments (amphotericin B vs. saline) to see which one works better as maintenance therapy for people with chronic pulmonary aspergillosis. It aims to find a convenient way to keep the infection under control after initial treatment.
Hear when a new Aspergillosis Invasive trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.